

# **HHS Public Access**

*J Mol Cell Cardiol*. Author manuscript; available in PMC 2016 August 01.

Published in final edited form as:

Author manuscript

*J Mol Cell Cardiol*. 2015 August ; 85: 240–248. doi:10.1016/j.yjmcc.2015.06.009.

## **Oxidation of Ryanodine Receptor (RyR) and Calmodulin enhance Ca release and pathologically alter RyR structure and Calmodulin affinity**

**Tetsuro Oda**1,2, **Yi Yang**1,3, **Hitoshi Uchinoumi**1, **David D. Thomas**3, **Ye Chen-Izu**1, **Takayoshi Kato**2, **Takeshi Yamamoto**2, **Masafumi Yano**2, **Razvan L. Cornea**3, and **Donald M. Bers**1,#

<sup>1</sup>Department of Pharmacology University of California, Davis, CA

<sup>2</sup>Department of Medicine and Clinical Science, Division of Cardiology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi

<sup>3</sup>Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN

## **Abstract**

Oxidative stress may contribute to cardiac ryanodine receptor (RyR2) dysfunction in heart failure (HF) and arrhythmias. Altered RyR2 domain-domain interaction (domain unzipping) and calmodulin (CaM) binding affinity are allosterically coupled indices of RyR2 conformation. In HF RyR2 exhibits reduced CaM binding, increased domain unzipping and greater SR Ca leak, and dantrolene can reverse these changes. However, effects of oxidative stress on RyR2 conformation and leak in myocytes are poorly understood. We used fluorescent CaM, FKBP12.6, and domainpeptide biosensor (F-DPc10) to measure, directly in cardiac myocytes, (1) RyR2 activation by hydrogen peroxide  $(H_2O_2)$ -induced oxidation, (2) RyR2 conformation change caused by oxidation, (3) CaM-RyR2 and FK506-binding protein (FKBP12.6)-RyR2 interaction upon oxidation, and (4) whether dantrolene affects  $1-3$ .  $H_2O_2$  was used to mimic oxidative stress.  $H_2O_2$ significantly increased the frequency of  $Ca^{2+}$  sparks and spontaneous  $Ca^{2+}$  waves, and dantrolene almost completely blocked these effects.  $H_2O_2$  pretreatment significantly reduced CaM-RyR2 binding, but had no effect on FKBP12.6-RyR2 binding. Dantrolene restored CaM-RyR2 binding but had no effect on intracellular and RyR2 oxidation levels.  $H_2O_2$  also accelerated F-DPc10- $RyR2$  association while dantrolene slowed it. Thus,  $H_2O_2$  causes conformational changes (sensed by CaM and DPc10 binding) associated with Ca leak, and dantrolene reverses these RyR2 effects. In conclusion, in cardiomyocytes,  $H_2O_2$  treatment markedly reduces the CaM-RyR2 affinity, has no effect on FKBP12.6-RyR2 affinity, and causes domain unzipping. Dantrolene can correct

**Disclosures**

Address for Correspondence: Donald M. Bers, PhD, Department of Pharmacology, University of California, Davis, 451 Health Science Drive, Davis, CA 95616, Phone (530) 752-3200, FAX (530) 752-7710, dmbers@ucdavis.edu.

The authors report no conflicts of interest.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

domain unzipping, restore CaM-RyR2 affinity, and quiet pathological RyR2 channel gating. F-DPc10 and CaM are useful biosensors of a pathophysiological RyR2 state.

#### **Keywords**

Calmodulin; FKBP12.6; Ryanodine Receptor; Reactive oxygen species; Dantrolene

## **1. Introduction**

The  $Ca^{2+}$  release channel in cardiac sarcoplasmic reticulum (SR) is the type 2 ryanodine receptor (RyR2), which is pivotal in cardiac excitation-contraction coupling [1]. Several lines of evidence suggest that excessive  $Ca^{2+}$  leak through RyR2, in diastole, is seen in pathological conditions, such as heart failure (HF), leading to both systolic and diastolic dysfunction [2–7]. This abnormal RyR2  $Ca^{2+}$  leak can cause delayed afterdepolarization (DAD) that can lead to lethal arrhythmias, such as catecholaminergic polymorphic ventricular tachycardia (CPVT) that is linked to human RyR2 mutations. Stabilization of RyR2 closed state, resulting in suppression of abnormal SR  $Ca^{2+}$  leak, is a promising new therapeutic strategy against HF or lethal arrhythmias.

In our recent studies, we have proposed that altered RyR2 conformation, especially of an interaction between the N-terminal and central domains of the RyR2, destabilizes the RyR2 channel gating and contributes to the abnormal  $Ca^{2+}$  leak [4,8–12]. In normal conditions, the interaction between these domains is tight (zipped state), and stabilizes the closed RyR2 channel. On the other hand, in disease conditions, the interaction between N-terminal and central domains is weakened (unzipped state), resulting in an abnormally high  $Ca^{2+}$  leak via RyR2. This altered domain interaction (domain unzipping) may be diagnostic of a pathological RyR2 gating state that contributes to dysfunction.

A domain peptide corresponding to a sequence span within the central domain of RyR2 residues 2460–2495 (DPc10), that includes a CPVT mutation site (R2474S), can bind to the native N-terminal domain, competing with its normal interaction with the central domain. By inducing domain unzipping, DPc10 increases RyR2 leakiness in the normal cardiac myocytes or SR vesicles [4,11]. We have recently proposed that the binding kinetics of fluorescent DPc10 (F-DPc10) to the RyR2 in permeabilized cardiomyocytes is a sensitive measure of RyR2 conformational change to the pathological unzipped state [12].

Calmodulin (CaM) binds to and inhibits RyR2 opening at both high and low  $\lbrack Ca^{2+} \rbrack$  [13,14]. We have shown that CaM-RyR2 binding affinity is reduced in HF [3,15] and that this increases RyR2  $Ca^{2+}$  leak, as seen in HF or in knock-in (KI) mice carrying a human CPVTassociated RyR2 mutation (R2474S) or an RyR2 mutation that prevents CaM binding [15,16]. We also showed that CaM binding to RyR2 stabilizes the zipped state, suppresses DPc10 access and inhibits RyR2 leak. Reciprocally, domain unzipping inhibits CaM-RyR2 binding, which in turn causes abnormal  $Ca^{2+}$  leak from RyR2 [12].

Reactive oxygen species (ROS) are thought to be involved in a variety of cardiovascular diseases, including HF [17–19]. ROS can also cause RyR2 dysfunction by oxidation of thiol

groups of cysteine residues in the RyR2 channel [20]. However, the relation between oxidation-induced RyR2 dysfunction and either CaM binding affinity or the pathological unzipped state is not clear, especially in the myocyte environment.

Dantrolene is the only specific and effective therapeutic agent for treatment of malignant hyperthermia that occurs in certain patients during or following surgery or anesthesia.<sup>21</sup> In HF or CPVT-KI mouse, dantrolene has been reported to correct domain unzipping by binding to the N-terminal (601–620) domain of RyR2, and thereby inhibit diastolic  $Ca^{2+}$ leak via RyR2 [11,22,23].

In the present study, we investigated directly in cardiac myocytes how moderate oxidative stress, as in HF, alters RyR2 conformation, as detected by measuring the fluorescently labeled DPc10 (F-DPc10) binding kinetics, and the binding affinity of fluorescent CaM and FKBP12.6. Furthermore, we assessed how dantrolene affects RyR2 conformation change and the binding affinity of CaM-RyR2 and FKBP12.6-RyR2.

## **2. Materials and methods**

Rat ventricular myocytes were isolated and permeabilized as previously described [24]. The care of the animals and procedures were approved by the University of California, Davis Animal Research Committee in accordance with the NIH Guide for the Care and Use of Laboratory Animals, and Guidelines of the Animal Ethics Committee of Yamaguchi University School of Medicine. FKBP12.6 and CaM were labeled with Alexa Fluor 488 (F-FKBP12.6, F-CaM, respectively) and DPc10 was labeled with HiLyte Fluor 647 (F-DPc10, respectively) at AnaSpec as in our previous studies [12,25,26]. Online Figure IA–C shows hydrogen peroxide  $(H_2O_2)$  did not alter both AF488 and F-CaM fluorescence intensity. All experiments were performed at room temperature (25°C). An expanded Materials and Methods section can be found in the Online Data Supplement.

## **3. Results**

#### **3.1. Activated RyR2 Function by Oxidation in Myocytes**

Oxidation induced by  $H_2O_2$  is expected to activate SR Ca<sup>2+</sup> leak through RyR2 at diastolic [Ca<sup>2+</sup>]<sub>i</sub> [27,28]. We used line-scan images to measure the effects of 50  $\mu$ M H<sub>2</sub>O<sub>2</sub> on Ca<sup>2+</sup> spark frequency (CaSpF) and SR Ca<sup>2+</sup> content (evaluated via rapid caffeine application) in intact cardiomyocytes after 1 Hz electric field stimulation (Fig 1).  $H_2O_2$  treatment can also inhibit SR Ca<sup>2+</sup>-ATPase (SERCA) activity [29,30]. Under our conditions neither  $H_2O_2$  nor dantrolene significantly altered  $Ca^{2+}$  transient amplitude or time constant of  $[Ca^{2+}]$ <sub>i</sub> decline (Table SI). This indicates that 50  $\mu$ M H<sub>2</sub>O<sub>2</sub> had negligible effect on SERCA function. Fig 1A–1B, and Table SII show that  $H_2O_2$  significantly increased the CaSpF and Ca<sup>2+</sup> spark full duration at half maximum compared with control. Thus  $H_2O_2$  may enhance diastolic RyR2 channel opening. CaSpF depends on SERCA-dependent SR Ca<sup>2+</sup> content [31], but  $H_2O_2$  did not significantly alter SR Ca<sup>2+</sup> content. So CaSpF normalized to SR Ca<sup>2+</sup> content, was significant increase by  $H_2O_2$  treatment of myocytes (Fig 1C).

We also tested whether  $H_2O_2$  enhanced the propensity for arrhythmogenic DADs, as measured by spontaneous  $Ca^{2+}$  waves (SCW) in intact cardiac myocytes. Fig 2A–2B shows

that  $H_2O_2$  treatment significantly increased the occurrence of SCW vs. control when the pacing rate increased from 1 to 5 Hz.

#### **3.2. Dantrolene Quiets Oxidation-induced RyR2 Activation**

Dantrolene can prevent abnormal  $Ca^{2+}$  leak in CPVT KI and HF models [11,22,23,32]. To test whether dantrolene could prevent  $H_2O_2$ -induced increase in CaSpF, dantrolene was added to myocytes before  $H_2O_2$  treatment. Dantrolene pretreatment had no effect on control myocytes, but suppressed the  $H_2O_2$ -induced increase in frequency of  $Ca^{2+}$  sparks and SCW (Fig 1 and 2). To test whether dantrolene prevented these  $H_2O_2$  effects on RyR2 by reducing the oxidative level in myocytes, we assessed oxidation levels in myocytes.

#### **3.3. H2O2-Induced Intracellular and RyR2 Redox Modification**

To monitor intracellular ROS level, we used  $H_2$ DCFDA (10  $\mu$ M). Fig 3A shows confocal  $H<sub>2</sub> DCFDA$  fluorescence images in control or  $H<sub>2</sub>O<sub>2</sub>$ -treated myocytes with or without dantrolene. As shown in Fig 3B, the intracellular ROS level was similarly increased after addition of 50  $\mu$ M H<sub>2</sub>O<sub>2</sub>, with or without dantrolene pretreatment. Thus, dantrolene does not alter the intracellular oxidative level overall. To assess whether dantrolene can attenuate the extent of RyR2 thiol modification in  $H_2O_2$ -treated myocytes, we assayed monobromobimane (mBB) fluorescence-labeling. Fig 3C–D shows that  $H_2O_2$  treatment significantly decreased the content of free thiols on RyR2, regardless of dantrolene pretreatment. Taken together, these results indicate that dantrolene does not attenuate intracellular ROS or RyR2 Cys oxidation.

#### **3.4. H2O2 does not alter FKBP12.6 Binding at Z-line in Permeabilized Myocytes**

We assessed the molecular mechanism by which RyR2 activity was increased by  $H_2O_2$ induced oxidative stress. FKBP12.6 can bind to and stabilize RyR2 channel gating, but details are controversial [33]. We measured the effect of  $H_2O_2$  on FKBP12.6-RyR2 binding affinity in saponin-permeabilized myocytes using AF488-FKBP12.6 [15,25,26,34,35]. Fig 4A shows confocal images of F-FKBP with or without  $H_2O_2$ , and also with 1  $\mu$ M of the specific  $Ca^{2+}/CaM$ -dependent kinase II (CaMKII) inhibitor autocamtide-2-related inhibitory peptide (AIP) or 1  $\mu$ M dantrolene. We used 1 nM F-FKBP (near the  $K_d$ ) [26], because at half-saturation it would be very sensitive to either an increase or decrease in RyR2 binding. Neither  $H_2O_2$  nor AIP nor dantrolene altered Z-line (F<sub>Z</sub>) and M-line (F<sub>M</sub>) F-FKBP12.6 fluorescence (Fig 4B), indicating  $H_2O_2$  failed to alter specific F-FKBP12.6 binding to the RyR2 ( $F_Z-F_M$ ) in permeabilized myocytes, with or without AIP or dantrolene (Fig 4C). Thus H2O2 did not alter FKBP12.6-RyR2 affinity.

#### **3.5. Effect of H2O2 on CaM Binding to Z-line in Permeabilized Myocytes**

CaM also binds to RyR2 and reduces RyR2 open probability, and works as a regulatory protein for RyR2 channel gating [13–15,36]. We measured the effect of  $H_2O_2$  on CaM-RyR2 binding affinity using F-CaM as in our previous reports [15,25]. Fig 5A–B shows that both 10 and 50 μM  $H_2O_2$  myocyte pretreatment reduced the F-CaM binding at the Z-line significantly, (using  $[F-CaM] = 20$  nM, near its  $K<sub>d</sub>$  [15]), but did not alter CaM at the M-line (Online Fig IIA). This indicates that  $H_2O_2$  decreased affinity of F-CaM/RyR2 binding.

However, because  $H_2O_2$  was not removed before CaM addition, this effect might be due to oxidation of either RyR2 or CaM, particularly because methionines on CaM can be oxidized and cause reduced binding to RyR2 [36].

To test whether CaM oxidation can explain the reduced RyR2 binding of  $H_2O_2$ -treated myocytes, we first incubated [F-CaM] (50  $\mu$ M) for 60 min in media containing 50  $\mu$ M H<sub>2</sub>O<sub>2</sub> (the concentration used in pre-incubated myocytes). This allowed F-CaM oxidation (and we call this F-CaM<sup>Ox</sup>). This was then diluted 2500-fold to 20 nM F-CaM<sup>Ox</sup> and no  $H_2O_2$  was present in the myocyte bath. As shown in Fig 5C–D (and Online Figure IIC–D), F-CaMOx binds less well to RyR2, but this 20% reduction is smaller than the 50% seen when F-CaM applied to myocytes pre-treated with 50 μM H<sub>2</sub>O<sub>2</sub> (Fig 5A–B). This suggests that both CaM and RyR2 oxidation contribute to the reduced CaM binding. It also suggests that CaM was not fully oxidized, by our in vitro pre-exposure to 50  $\mu$ M H<sub>2</sub>O<sub>2</sub> (Balog used 1000 times higher  $H_2O_2$  concentration for 24 hr; [37]).

As a further test of whether RyR2 oxidation alone inhibits subsequent CaM affinity, we removed  $H_2O_2$  from myocytes by repeated washing, prior to the addition of F-CaM. Fig 6A shows confocal images of F-CaM binding at the Z-line. Myocyte oxidation (by 50 μM  $H_2O_2$ ) dramatically reduced specific binding of F-CaM at the Z-line (F<sub>Z</sub>-F<sub>M</sub>) by 32% (Fig 6B) without altering the M-line fluorescence (Online Fig IIB). That is consistent with data in Fig 5, and that ~60% of the reduced CaM binding in Fig 5B was due to  $H_2O_2$ -induced changes at RyR2, with the remainder due to effects on CaM. Dantrolene  $(1 \mu M)$ , but not the CaMKII inhibitor AIP, partially restored F-CaM binding in  $H_2O_2$ -treated myocytes (Fig 6B). These results indicate that  $H_2O_2$ -induced loss of CaM binding can be restored by dantrolene. The lack of AIP effect suggests that any CaMKII activation by  $H_2O_2$  in this protocol does not contribute to the acute loss of CaM-RyR2 binding. Neither AIP nor dantrolene alter the CaM-RyR2 affinity under control conditions (Fig 6D and Online Fig III).

## **3.6. Effects of Dantrolene or H2O2 on Wash-In Kinetics of HF647-DPc10**

Since CaM binding to RyR2 in myocytes is known to suppress  $Ca^{2+}$  sparks [15,38], the  $H_2O_2$ -induced increase in SR Ca<sup>2+</sup> leak (measured as Ca<sup>2+</sup> sparks in Fig 1) might be mediated mainly by the oxidation of RyR2 and CaM and reduced CaM binding to the RyR2. The restoration of CaM binding (and normal Ca sparks) by dantrolene raised a connection to our recent work [12]. We had shown that RyR2 CaM binding exhibits negative allosteric coupling with the accessibility of the unzipping peptide DPc10 (DPc10 binding inhibits CaM binding, and CaM binding inhibits DPc10 access [12]). Dantrolene may shift this balance toward the more normal state [22,23] by reducing DPc10 accessibility (zipping) and also increasing CaM affinity. We tested whether  $H_2O_2$  treatment enhances DPc10 access and whether that was sensitive to dantrolene (as shown above for CaSpF and CaM binding).

We previously reported that the wash-in kinetics of DPc10 labeled with HyLite Fluor 647 (F-DPc10) were greatly slowed when CaM was bound to RyR2, which also prevented RyR2 activation by DPc10 exposure [12]. Our working model was that DPc10 access to its binding site was sterically blocked when CaM was bound. Here, we first tested whether dantrolene has the same effect as CaM in preventing DPc10 access.

Fig 7A shows confocal images of F-DPc10 binding after 200 min of incubation. Fig 7B shows the time course of F-DPc10 wash-in with or without 1 μM dantrolene. Dantrolene reduced maximal F-DPc10 binding  $(B_{\text{max}})$  by >70% (Fig 7C), without altering M-line fluorescence (Online Fig IV). This suggests that dantrolene keeps RyR2 conformationally closed with respect to access of DPc10. However, these results could also result from competition between F-DPc10 and dantrolene to a site on RyR2. To test this hypothesis, we measured the F-DPc10 wash-out kinetics, with or without dantrolene. Online Fig VA–B shows that non-fluorescent DPc10 (NF-DPc10) can accelerate the wash-out kinetics of F-DPc10. This is consistent with our previous report that F-DPc10 and NF-DPc10 bind at the same binding site [12]. However, dantrolene had no effect on F-DPc10 wash-out kinetics, indicating that F-DPc10 and dantrolene binding sites are separate (Online Fig VC–D). This also suggests that the slow binding of F-DPc10 (and effect of dantrolene thereon) is due to on-rate effects, consistent with a RyR2 conformation that strongly limits access of DPc10 to its site on RyR2.

Next, we tested whether RyR2 oxidation would increase F-DPc10 access. Here, we used FRET between F-FKBP12.6 as a donor and F-DPc10 as an acceptor, to detect DPc10 that specifically binds at RyR2 [12]. Note that F-FKBP12.6 binds specifically at RyR2 with 1 nM affinity, and its binding is not influenced by CaM [26],  $H_2O_2$  or dantrolene (Fig 4). FRET was assessed as the decrease in F-FKBP12.6 donor fluorescence intensity by binding of F-DPc10 acceptor in its proximity, i.e. donor quench, as in our previous report [12].  $H_2O_2$ pre-incubation significantly accelerated the rate of F-DPc10 binding compared with control (Fig 8A–B). This indicates that RyR2 oxidation enhances DPc10 access (e.g. by causing domain unzipping). Furthermore, pre-equilibration with dantrolene in  $H_2O_2$ -treated myocytes reversed the  $H_2O_2$ -induced acceleration of access (Fig 8B) and reduced the maximal extent of quench (Fig 8C), which reflects a decrease in  $B_{max}$  of F-DPc10. Taken together, these findings show, for the first time in situ, that  $H_2O_2$  leads to defective RyR2 domain unzipping and dantrolene can correct this conformational change as well as restoring CaM affinity.

## **4. Discussion**

Novel findings of this study are the following: In permeabilized ventricular myocyte environment, (1)  $H_2O_2$  treatment increases both CaSpF and the occurrence of SCW, but dantrolene prevents this elevated Ca<sup>2+</sup> leak; (2) RyR2 oxidation by H<sub>2</sub>O<sub>2</sub> decreases its binding affinity for CaM, but does not alter its FKBP12.6 affinity; (3) RyR2 oxidation leads to domain unzipping (high DPc10 access); and (4) dantrolene corrects domain unzipping, restores the CaM-RyR2 binding affinity, and inhibits pathological RyR2 channel gating. Our working model is that modest  $H_2O_2$  (or ROS) levels cause a similar pathological change in RyR2 conformation as seen in HF, in which CaM affinity is reduced, DPc10 access is increased and SR Ca leak is elevated.

## **4.1. RyR2 Function is Activated by H2O<sup>2</sup>**

Increased ROS production has been associated with pathological states, such as HF [39], and RyR2 activity in pathological states is increased by thiol oxidation [40,41].  $H_2O_2$  can activate RyR2 function, but also alter function of other important  $Ca^{2+}$ -handing proteins,

including SERCA and the Na<sup>+</sup>-Ca<sup>2+</sup> exchanger (NCX). Yan et al. [28] showed that CaSpF increased during 10 min of treatment with 50  $\mu$ M H<sub>2</sub>O<sub>2</sub> in intact myocytes. On the other hand, higher  $[H_2O_2]$  (200 μM) can reduce  $Ca^{2+}$  transient amplitude, CaSpF, and SR Ca<sup>2+</sup> content, consistent with  $H_2O_2$ -dependent inhibition of SERCA activity [30]. To assess whether  $H_2O_2$  activates the RyR2 function, we measured CaSpF under conditions where both amplitude and the rate of  $Ca^{2+}$  transient decline (reflecting SERCA activity), and the decay of caffeine-induced  $Ca^{2+}$  transient (reflecting NCX activity), were similar. This indicates that both SERCA and NCX function were not appreciably altered under our specific conditions. Thus, RyR2 function may be more sensitive to  $H_2O_2$ -induced modulation than are SERCA or NCX. We also found a significant increase in the occurrence of arrhythmogenic SCW in  $H_2O_2$ -treated myocytes, when pacing rate increased from 1 to 5 Hz, indicating that hyperactivity of RyR2 by oxidation may contribute to triggering lethal arrhythmias.

## **4.2. Dantrolene Reverses H2O2-Induced RyR2 Activation Without altering Cellular and RyR2 Oxidation**

Dantrolene has been shown to bind to amino acids 601–620 of RyR2 [42] and stabilize the RyR2 channel gating in pathological states, such as HF [32] or CPVT [43]. However, dantrolene has no effect on  $Ca^{2+}$  signaling under control condition [32,44]. These are consistent with our observation that dantrolene significantly reduced the CaSpF and prevented potentially deleterious spontaneous arrhythmogenic  $Ca^{2+}$  waves in H<sub>2</sub>O<sub>2</sub>-treated myocytes, but did not alter the frequency of  $Ca^{2+}$  sparks and SCW under control condition. To exclude the possibility that dantrolene attenuated the oxidation level to achieve this effect, we measured intracellular ROS production and RyR2 free thiol content in dantrolenetreated myocytes. Dantrolene influenced neither cellular nor RyR2 Cys oxidation level, suggesting that dantrolene directly stabilized RyR2, possibly by inhibiting domain unzipping [22]. Conceivably, dantrolene may indirectly affect RyR2 function via Met oxidation. However, the lack of significant effects on the overall cell oxidation and on the RyR2 Cys oxidation make this an unlikely mechanism of dantrolene action.

## **4.3. H2O2 Reduced CaM, but not FKBP12.6 binding to RyR2**

There are two main possible explanations for  $H_2O_2$ -induced defective CaM binding to RyR2: (1) Oxidation of CaM inhibits the productive association of CaM with RyR2 or (2) Oxidation of RyR2 inhibits CaM binding. Balog et al. [37] reported that extensive in vitro oxidation of CaM abolishes the functional interaction between CaM and RyR2. That is consistent with our in situ observation that our much milder exposure to  $H_2O_2$  caused some CaM oxidation and reduction of binding to RyR2 (Fig 5C). On the other hand, it has been previously proposed [14] that RyR2 oxidation enhances RyR2 activity by decreasing CaM binding affinity. This also agrees with our myocyte result that RyR2 oxidation reduced subsequent CaM binding (Fig 6). Taken together, these results strongly support the conclusion that oxidation of both CaM and RyR2 cause reduced CaM-RyR2 binding and this combined mechanism contributes to RyR2 dysfunction during oxidative stress. One of the interesting findings here is that dantrolene restores the CaM-RyR2 binding in  $H_2O_2$ treated myocytes, resulting in lower resting RyR2 leak, as has been seen for dantrolene in

HF or CPVT models [45,23], without changing intracellular and RyR2 oxidative level (Fig 3).

FKBP12.6 binds to RyR2 with high affinity and can also influence RyR2 gating [26,46,47], and has been proposed to play an important role in stabilizing RyR2 function [46–48], although this issue is controversial [26,30,49,50]. Shan *et al.* reported [48] that 1 mM  $H_2O_2$ combined with phosphorylation of Ser2808 by PKA could reduce FKBP12.6 binding to RyR2 by ~70%. In contrast, we find that neither PKA-dependent phosphorylation [26], DPc10-induced unzipping [12] nor the more moderate levels of  $H_2O_2$  used here (plausibly reflective of HF myocyte) had any effect on FKBP12.6 binding to RyR2 in myocytes (Fig 4). In our hands, CaM has much stronger effects on RyR2 function than does FKBP12.6, with more pronounced changes during pathophysiological conditions such as HF [15], oxidation or DPc10-induced unzipping.

#### **4.4. Dantrolene Corrects RyR2 Conformation Caused by either H2O2 or DPc10**

We previously demonstrated that monitoring F-DPc10 binding kinetics is a powerful tool to evaluate functionally important RyR2 conformational changes, likely related to an interaction between the N-terminal and central domains of RyR2. Using this method, we now show that  $H_2O_2$  significantly accelerates F-DPc10 association rate in situ, indicating that  $H_2O_2$  causes domain unzipping (Fig 8). We also found that dantrolene reduces access of F-DPc10 in either  $H_2O_2$ - or DPc10-treated myocytes, which suggests that  $H_2O_2$  and DPc10 induce similar structural changes that are both corrected by dantrolene (Fig 7 and 8). These findings are consistent with previous in vitro reports that oxidative stress of RyR2 (in SR vesicles) weakens domain interactions [51] and that dantrolene improves RyR2 function via correcting domain unzipping [22]. The  $B_{max}$  for F-DPc10 is lower in dantrolene-treated myocytes. That could have been a result of DPc10 and dantrolene competing at the same site. But we have ruled out that possibility. First, we measured the wash-out kinetics of F-DPc10 with or without NF-DPc10 in wash-out solution. Since F-DPc10 wash-out rate was faster with NF-DPc10 (Online Figure VA–B), we infer that F-DPc10 and NF-DPc10 bind to RyR2 at the same site. In contrast, dantrolene did not alter the wash-out kinetics of F-DPc10. These results suggest that dantrolene prevents F-DPc10 access (drastically reducing on-rate) without altering F-DPc10 dissociation (off-rate) (Online Figure VC–D). This observation supports the conclusions that F-DPc10 and dantrolene bind at separate sites on RyR2, and that dantrolene, like CaM [12], influences DPc10 access by an allosteric mechanism.

## **5. Limitations**

CaMKII can also be activated by oxidation at methionine 281/282 [52] and can also phosphorylate and activate RyR2 in pathological states [3,38,52–54]. This CaMKII pathway would be expected to exacerbate the direct ROS effects on CaM and RyR2 that alter RyR2 gating that has been our focus here. Here, we used the CaMKII inhibitors AIP (CaM binding experiments) and KN-93 (SCW experiments) specifically to assess CaMKII-independent effects of  $H_2O_2$  on  $Ca^{2+}$  waves and CaM binding to RyR2. Wagner *et al.* [27] have shown that the increase in CaSpF and SR Ca leak observed with 200  $\mu$ M H<sub>2</sub>O<sub>2</sub> was not prevented by KN-93, consistent with a CaMKII-independent effect of  $H_2O_2$  on RyR2 dysfunction.

Future studies will be required to clarify the detailed relation between ROS effects on CaM and RyR2 directly and those mediated indirectly via CaMKII-dependent phosphorylation of RyR2.

## **6. Conclusion**

Our results indicate that abnormal oxidative modification of RyR2 by  $H_2O_2$  causes reduced CaM affinity of RyR2 (by oxidation of sites on both CaM and RyR2) and RyR2 conformation changes (domain unzipping) that lead to untimely and potentially arrhythmogenic RyR2 channel opening. Dantrolene restores normal CaM binding and conformational state, and quiets pathological RyR2 channel gating (but has no effect on RyR2 function under control normal conditions). This  $H_2O_2$ -induced structural unzipping, reduced CaM binding and more active RyR2 may represent a functionally integrated common pathological RyR2 state that is relevant for HF, oxidative stress and even CPVTlinked genetic mutations.

## **Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.

## **Acknowledgments**

#### **Sources of Funding**

This work was supported by National Institutes of Health R01-HL092097 (DMB and RLC), R37HL30077 (DMB) and R37AG26160 (DDT), by JSPS KAKENHI Grant Number 26670403, and by SENSHIN Medical Research Foundation (TO).

## **Non-standard Abbreviations and Acronyms**





## **References**

- 1. Bers DM. Macromolecular complexes regulating cardiac ryanodine receptor function. J Mol Cell Cardiol. 2004; 37:417–429. [PubMed: 15276012]
- 2. Marks AR. Cardiac Intracellular Calcium Release Channels: Role in Heart Failure. Circ Res. 2000; 87:8–11. [PubMed: 10884365]
- 3. Ai X, Curran JW, Shannon TR, Bers DM, Pogwizd SM.  $Ca^{2+}/c$ almodulin dependent protein kinase modulates cardiac ryanodine receptor phosphorylation and sarcoplasmic reticulum Ca2+ leak in heart failure. Circ Res. 2005; 97:1314–1322. [PubMed: 16269653]
- 4. Oda T, Yano M, Yamamoto T, Tokuhisa T, Okuda S, Doi M, et al. Defective regulation of interdomain interactions within the ryanodine receptor plays a key role in the pathogenesis of heart failure. Circulation. 2005; 111:3400–3410. [PubMed: 15967847]
- 5. Bers DM. Cardiac Sarcoplasmic Reticulum Calcium Leak: Basis and Roles in Cardiac Dysfunction. Ann Rev Physiol. 2014; 76:107–127. [PubMed: 24245942]
- 6. Piacentino V 3rd, Weber CR, Chen X, Weisser TJ, Margulies KB, Bers DM, et al. Celluar basis of abnormal calcium transients of failing human ventricular myocytes. Circ Res. 2003; 92:651–658. [PubMed: 12600875]
- 7. Belevych AE, Terentyev D, Terentyeva R, Nishijima Y, Sridhar A, Hamlin RL, et al. The relationship between arrhythmogenesis and impaired contractility in heart failure: role of altered ryanodine receptor function. Cardiovasc Res. 2011; 90:493–502. [PubMed: 21273243]
- 8. Ikemoto N, Yamamoto T. Regulation of calcium release by interdomain interaction within ryanodine receptor. Front Biosci. 2002; 7:d671–d683. [PubMed: 11861212]
- 9. Ikemoto, N. Intra-molecular domain-domain interaction: a key mechanism for calcium channel regulation of ryanodine receptor. In: Wehrens, XHT.; Marks, AR., editors. Ryanodine Receptors: Structure, Function and Dysfunction in Clinical Disease. 2004. p. 53-65.
- 10. Yamamoto T, EI-Hayek R, Ikemoto N. Postulated role of interdomain interaction within the ryanodine receptor in Ca2+ channel regulation. J Biol Chem. 2000; 275:11618–11625. [PubMed: 10766778]
- 11. Uchinoumi H, Yano M, Suetomi T, Ono M, Xu X, Tateishi H, et al. Catecholaminergic polymorphic ventricular tachycardia is caused by mutation-linked defective conformational regulation of the ryanodine receptor. Circ Res. 2010; 106:1413–1424. [PubMed: 20224043]
- 12. Oda T, Yang Y, Nitu FR, Svensson B, Lu X, Fruen BR, Cornea RL, et al. In cardiomyocytes, binding of unzipping peptide activates ryanodine receptor 2 and reciprocally inhibits calmodulin binding. Circ Res. 2013; 112:487–497. [PubMed: 23233753]
- 13. Yamaguchi N, Xu L, Pasek DA, Evans KE, Meissner G. Molecular basis of calmodulin binding to cardiac muscle Ca2+ release channel (ryanodine receptor). J Biol Chem. 2003; 278:23480–23486. [PubMed: 12707260]
- 14. Balshaw DM, Xu L, Yamaguchi N, Pasek DA, Meissner G. Calmodulin binding and inhibition of cardiac muscle calcium release channel (ryanodine receptor). J Biol Chem. 2001; 276:20144– 20153. [PubMed: 11274202]

- 15. Yang Y, Guo T, Oda T, Chakraborty A, Chen L, Uchinoumi H, et al. Cardiac myocyte Z-line calmodulin is mainly RyR2-bound, and reduction is arrhythmogenic and occurs in heart failure. Circ Res. 2014; 114:295–306. [PubMed: 24186966]
- 16. Xu X, Yano M, Uchinoumi H, Hino A, Suetomi T, Ono M, et al. Defective calmodulin binding to the cardiac ryanodine receptor plays a key role in CPVT-associated channel dysfunction. Biochem Biophys Res Commun. 2010; 394:660–666. [PubMed: 20226167]
- 17. Tsutsui H, Ide T, Hayashidani S, Suematsu N, Utsumi H, Nakamura R, et al. Greater susceptibility of failing cardiac myocytes to oxygen free radical-mediated injury. Cardiovasc Res. 2001; 49:103– 109. [PubMed: 11121801]
- 18. Kinugawa S, Tsutsui H, Hayashidani S, Ide T, Suematsu N, Satoh S, et al. Treatment with dimethylthiourea prevents left ventricular remodeling and failure after experimental myocardial infarction in mice: role of oxidative stress. Circ Res. 2000; 87:392–398. [PubMed: 10969037]
- 19. Mallat Z, Philip I, Lebret M, Chatel D, Maclouf J, Tedgui A. Elevated levels of 8-iso-prostaglandin F2alpha in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. Circulation. 1998; 97:1536–1539. [PubMed: 9593557]
- 20. Meissner G. Regulation of mammalian ryanodine receptors. Front Biosci. 2002; 7:d2072–d2080. [PubMed: 12438018]
- 21. Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler F. Dantrolene a review of its pharmacology, therapeutic use and new developments. Anaesthesia. 2004; 59:364–373. [PubMed: 15023108]
- 22. Kobayashi S, Yano M, Suetomi T, Ono M, Tateishi H, Mochizuki M, et al. Dantrolene, a Therapeutic Agent for Malignant Hyperthermia, Markedly Improves the Function of Failing Cardiomyocytes by Stabilizing Interdomain Interactions Within the Ryanodine Receptor. J Am Coll Cardiol. 2009; 53:1993–2005. [PubMed: 19460614]
- 23. Kobayashi S, Yano M, Uchinoumi H, Suetomi T, Susa T, Ono M, et al. Dantrolene, a therapeutic agent for malignant hyperthermia, inhibits catecholaminergic polymorphic ventricular tachycardia in a RyR2 (R2474S/+) knock-in mouse model. Circ J. 2010; 74:2579–84. [PubMed: 20944434]
- 24. Li Y, Kranias EG, Mignery GA, Bers DM. Protein kinase A phosphorylation of the ryanodine receptor does not affect calcium sparks in mouse ventricular myocytes. Circ Res. 2002; 90:309– 316. [PubMed: 11861420]
- 25. Cornea RL, Nitu FR, Gruber S, Kohler K, Satzer M, Thomas DD, et al. FRET-based mapping of calmodulin bound to the RyR1  $Ca^{2+}$  release channel. Proc Natl Acad Sci USA. 2009; 106:6128– 6133. [PubMed: 19332786]
- 26. Guo T, Cornea RL, Huke S, Camors E, Yang Y, Picht E, et al. Kinetics of FKBP12.6 binding to ryanodine receptors in permeabilized cardiac myocytes and effects on Ca sparks. Circ Res. 2010; 106:1743–1752. [PubMed: 20431056]
- 27. Wagner S, Ruff HM, Weber SL, Bellmann S, Sowa T, Schulte T, et al. Reactive oxygen speciesactivated Ca/calmodulin kinase IIδ is required for late I(Na) augmentation leading to cellular Na and Ca overload. Circ Res. 2011; 108:555–65. [PubMed: 21252154]
- 28. Yan Y, Liu J, Wei C, Li K, Xie W, Wang Y, et al. Bidirectional regulation of Ca2+ sparks by mitochondria-derived reactive oxygen species in cardiac myocytes. Cardiovasc Res. 2008; 77:432–41. [PubMed: 18006452]
- 29. Qin F, Siwik DA, Lancel S, Zhang J, Kuster GM, Luptak I, et al. Hydrogen peroxide-mediated SERCA cysteine 674 oxidation contributes to impaired cardiac myocyte relaxation in senescent mouse heart. J Am Heart Assoc. 2013; 2:e000184. [PubMed: 23963753]
- 30. Greensmith DJ, Eisner DA, Nirmalan M. The effects of hydrogen peroxide on intracellular calcium handling and contractility in the rat ventricular myocyte. Cell Calcium. 2010; 48:341–51. [PubMed: 21106236]
- 31. Zima A, Bovo E, Bers DM, Blatter LA.  $Ca^{2+}$  spark-dependent and -independent sarcoplasmic reticulum  $Ca^{2+}$  leak in normal and failing rabbit ventricular myocytes. J Physiol. 2010; 588:4743– 57. [PubMed: 20962003]
- 32. Maxwell JT, Domeier TL, Blatter LA. Dantrolene prevents arrhythmogenic  $Ca^{2+}$  release in heart failure. Am J Physiol Heart Circ Physiol. 2012; 302:H953–63. [PubMed: 22180651]

- 33. Bers DM. Ryanodine receptor S2808 phosphorylation in heart failure: Smoking gun or red herring. Circ Res. 2012; 110:796–799. [PubMed: 22427320]
- 34. Guo T, Fruen BR, Nitu FR, Nguyen TD, Yang Y, Cornea RL, et al. FRET detection of calmodulin binding to the cardiac RyR2 calcium release channel. Biophys J. 2011; 101:2170–2177. [PubMed: 22067155]
- 35. Cornea RL, Nitu FR, Samso M, Thomas DD, Fruen BR. Mapping the ryanodine receptor FK506 binding protein subunit using fluorescence resonance energy transfer. J Biol Chem. 2010; 285:19219–19226. [PubMed: 20404344]
- 36. Yamaguchi N, Takahashi N, Xu L, Smithies O, Meissner G. Early cardiac hypertrophy in mice with impaired calmodulin regulation of cardiac muscle Ca release channel. J Clin Invest. 2007; 117:1344–1353. [PubMed: 17431507]
- 37. Balog EM, Norton LE, Thomas DD, Fruen BR. Role of calmodulin methionine residues in mediating productive association with cardiac ryanodine receptors. Am J Physiol Heart Circ Physiol. 2006; 290:H794–H799. [PubMed: 16199479]
- 38. Guo T, Zhang T, Mestril R, Bers DM. Ca/calmodulin-dependent protein kinase II phosphorylation of ryanodine receptor does affect calcium sparks in mouse ventricular myocytes. Circ Res. 2006; 99:398–406. [PubMed: 16840718]
- 39. McMurray J, Chopra M, Abdullah I, Smith WE, Dargic HJ. Evidence of oxidative stress in chronic heart failure in humans. Eur Heart J. 1993; 14:1493–1498. [PubMed: 8299631]
- 40. Boraso A, Williams AJ. Modification of the gating of the cardiac sarcoplasmic reticulum  $Ca^{2+}$ release channel by  $H_2O_2$  and dithiothreitol. Am J Physiol. 1994; 267:H1010–H1016. [PubMed: 8092267]
- 41. Donoso P, Finkelstein JP, Montecinos L, Said M, Sánchez G, Vittone L, et al. Stimulation of NOX2 in isolated hearts reversibly sensitizes RyR2 channels to activation by cytoplasmic calcium. J Mol Cell Cardiol. 2014; 68:38–46. [PubMed: 24417961]
- 42. Paul-Pletzer K, Yamamoto T, Ikemoto N, Jimenez LS, Morimoto H, Williams PG, et al. Probing a putative dantrolene-binding site on the cardiac ryanodine receptor. Biochem J. 2005; 387:905–909. [PubMed: 15656791]
- 43. Jung CB, Moretti A, Mederos Y, Schnitzler M, Iop L, Storch U, et al. Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia. EMBO Mol Med. 2012; 4:180–191. [PubMed: 22174035]
- 44. Diaz-Sylvester PL, Porta M, Copello JA. Halothane modulation of skeletal muscle ryanodine receptors: dependence on  $Ca^{2+}$ ,  $Mg^{2+}$ , and ATP. Am J Physiol Cell Physiol. 2008; 294:C1103– C1112. [PubMed: 18305228]
- 45. Ono M, Yano M, Hino A, Suetomi T, Xu X, Susa T, et al. Dissociation of calmodulin from cardiac ryanodine receptor causes aberrant Ca2+ release in heart failure. Cardiovasc Res. 2010; 87:609– 617. [PubMed: 20388639]
- 46. Prestle J, Janssen PM, Janssen AP, Zeitz O, Lehnart SE, Bruce L, et al. Overexpression of FK506 binding protein FKBP12.6 in cardiomyocytes reduces ryanodine receptor-mediated Ca2+ leak from the sarcoplasmic reticulum and increases contractility. Circ Res. 2001; 88:188–194. [PubMed: 11157671]
- 47. Marx SO, Gaburjakova M, Henrikson C, Ondrias K, Marks AR. Coupled gating between cardiac calcium release channels (ryanodine receptors). Circ Res. 2001; 88:1151–1158. [PubMed: 11397781]
- 48. Shan J, Betzenhauser MJ, Kushnir A, Reiken S, Meli AC, Wronska A, et al. Role of chronic ryanodine receptor phosphorylation in heart failure and β-adrenergic receptor blockade in mice. J Cin Invest. 2010; 120:4375–4387.
- 49. Stange M, Xu L, Balshaw D, Yamaguchi N, Meissner G. Characterization of recombinant skeletal muscle (Ser-2843) and cardiac muscle (Ser-2809) ryanodine receptor phosphorylation mutants. J Biol Chem. 2003; 278:51693–51702. [PubMed: 14532276]
- 50. Houser SR. Role of RyR2 phosphorylation in heart failure and arrhythmias: protein kinase Amediated hyperphosphorylation of the ryanodine receptor at serine 2808 does not alter cardiac contractility or cause heart failure and arrhythmias. Circ Res. 2014; 114:1320–1327. [PubMed: 24723657]

- 51. Yano M, Okuda S, Oda T, Tokuhisa T, Tateishi H, Mochizuki M, et al. Correction of defective interdomain interaction within ryanodine receptor by antioxidant is a new therapeutic strategy against heart failure. Circulation. 2005; 112:3633–3643. [PubMed: 16330705]
- 52. Erickson JR, Joiner ML, Guan X, Kutschke W, Yang J, Oddis CV, et al. A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation. Cell. 2008; 133:462–474. [PubMed: 18455987]
- 53. Kohlhaas M, Zhang T, Seidler T, Zibrova D, Dybkova N, Steen A, et al. Circ Res. 2006; 98:235– 244. [PubMed: 16373600]
- 54. Curran J, Brown KH, Pogwizd S, Bers DM, Shannon TR. Spontaneous Ca waves in ventricular myocytes from failing hearts depend on Ca2+-calmodulin-dependent protein kinase II. J Mol Cell Cardiol. 2010; 49:25–32. [PubMed: 20353795]

## **Highlights**

- **•** RyR2 oxidation reduces CaM binding affinity, but does not alter FKBP12.6 binding.
- **•** Oxidation leads to defective domain interactions (unzipping) within RyR2.
- **•** Dantrolene prevents oxidation-induced RyR2 unzipping and loss of CaM-RyR2 affinity.
- **•** Dantrolene inhibits pathological RyR2 channel gating.



## **Fig 1.**

Effects of H<sub>2</sub>O<sub>2</sub> and dantrolene on Ca<sup>2+</sup> sparks and SR Ca<sup>2+</sup> content in intact myocytes.  $Ca<sup>2+</sup>$  sparks and SR  $Ca<sup>2+</sup>$  content were measured in myocytes which were treated or not for 5 min with 50 μM H<sub>2</sub>O<sub>2</sub>. Some myocytes were also pretreated for 2 hours with 1 μM dantrolene (DAN). (A) Representative line-scan images of  $Ca^{2+}$  sparks. (B) Summarized data of CaSpF and SR Ca<sup>2+</sup> content. Data are reported as mean  $\pm$  SE (n values on bars). \*P<0.05 vs. Control, # P<0.05 vs.  $H_2O_2$ .



#### **Fig 2.**

Arrhythmogenic spontaneous Ca<sup>2+</sup> waves (SCW) following treatment with  $H_2O_2$  in intact myocytes. (A) Treatment with  $H_2O_2$  (50  $\mu$ M; 3min) led to an increased incidence of SCW (arrows), but dantrolene (DAN) prevented SCW. Representative time-plots of intracellular  $Ca<sup>2+</sup>$  during pacing. (B) Summary of % occurrence of SCW. Numbers inside the bars indicate cells with SCW/total cells studied for each group. \*P<0.05 vs. Control, Fisher's exact test.



#### **Fig 3.**

Oxidation status of the intracellular environment and RyR2. (A) Representative confocal images of control,  $H_2O_2$  (50  $\mu$ M), and  $H_2O_2$  (50  $\mu$ M)+DAN (1  $\mu$ M) loaded with an ROSsensitive fluorescent indicator  $H_2$ DCFDA (10 μM). (B) Time course of  $H_2$ DCFDA fluorescence recorded under the same condition as indicated for panel A (left), and quantitative analysis of the  $H_2$ DCFDA fluorescence intensity at equilibrium for each condition (right). (C) Representative RyR2-bound mBB fluorescence intensity (upper strip) and Coomassie-stained gels (lower strip) of RyR2 measured under control conditions,  $+H_2O_2$  (50 μM), or  $+H_2O_2$  (50 μM)+DAN (1 μM) treatment. (D) Relative free thiol content of RyR2 (indicated by mBB fluorescence) normalized by the corresponding intensity of the Coomassie – stained RyR2 band. Data are reported as mean  $\pm$  SE (n values on bars). DAN: dantrolene.



## **Fig 4.**

Effect of  $H_2O_2$  (50 µM) on FKBP12.6 binding at the Z-line. (A) Representative confocal images of saponin-permeabilized myocytes incubated with F-FKBP (1 nM), which were exposed to  $H_2O_2$  (50 μM),  $H_2O_2$  (50 μM) +AIP (1 μM) or  $H_2O_2$  (50 μM) +DAN (1 μM). (B) F-FKBP fluorescence intensity (normalized to Z-line at control) from Z-line and M-line. (C) Summary of the specific binding of F-FKBP at Z-line  $(F_Z-F_M)$  corresponding to the experiment in panel A. Data are reported as mean ± SE (n values on bars). DAN: dantrolene.



#### **Fig 5.**

Effects of myocyte or F-CaM oxidation by  $H_2O_2$  on F-CaM binding at the Z-line. (A) Representative confocal images illustrating the effect of myocyte oxidation by  $H_2O_2$  on F-CaM binding at the Z-lines ( $F_Z - F_M$ ). H<sub>2</sub>O<sub>2</sub> was applied to the bath 1 hour before beginning to image and was present throughout the experiment. (B) Quantitative analysis of data from A, normalized to  $F_Z - F_M$  at control. (C) Representative confocal images of the effect of F-CaM oxidation on specific binding at the Z-line  $(F_Z - F_M)$ . F-CaM was pre-incubated in  $H<sub>2</sub>O<sub>2</sub>$ , then applied to the myocyte bath under control conditions (F-CaM<sup>Ox</sup>). (D) Quantitative analysis of data from C. Data are reported as mean  $\pm$  SE (n values on bars). \*p<0.001 vs. control.



#### **Fig 6.**

Effects of RyR2 oxidation or AIP and DAN on calmodulin (CaM) binding at the Z-line. (A)  $H<sub>2</sub>O<sub>2</sub>$  was applied to the myocyte bath 1 hour before beginning the recording, and was removed before the applying the F-CaM. Representative confocal images of the effects of  $H_2O_2$ ,  $H_2O_2$ +AIP, and  $H_2O_2$ +dantrolene on the specific binding of F-CaM binding at the Zlines ( $F_Z - F_M$ ). (B) Quantitative analysis of data from A. (C) Representative confocal image of the effects of AIP and DAN on F-CaM Z-line binding in control myocyte. (D) Quantitative analysis of data from C. Data are reported as mean  $\pm$  SE (n values on bars; a.u., arbitrary units). \*p<0.001 vs. control, #p<0.001 vs.  $H_2O_2$ . DAN: dantrolene.



## **Fig 7.**

Effect of dantrolene (DAN) (1 μM) on F-DPc10 (0.5 μM) binding at Z-line. (A) Representative confocal images illustrating the effect of dantrolene (1 μM) on the F-DPc10 (0.5 μM) binding at the Z-lines. (B) Time course of F-DPc10 (0.5 μM) wash-in (full circles), and in the presence of dantrolene (1  $\mu$ M, open circles). (C) Summary of B<sub>max</sub> and k<sub>in</sub> for the data in panel B. Data are reported as mean  $\pm$  SE (n values on bars).



#### **Fig 8.**

Effects of  $H_2O_2$  and dantrolene (DAN) on the F-DPc10 wash-in kinetics, detected via FRET between F-FKBP (donor) and F-DPc10 (acceptor). (A) FRET, detected as donor quenching in myocytes pre-equilibrated with H<sub>2</sub>O<sub>2</sub> (50  $\mu$ M) or H<sub>2</sub>O<sub>2</sub> (50  $\mu$ M) + DAN (1  $\mu$ M). (B) Summary of  $\tau_{\text{wash-in}}$  and  $\text{FRET}_{\text{max}}$  corresponding to the data in panel A. Data are reported as mean  $\pm$  SE (n values on bars). \*p<0.001 vs. control, #p<0.001 vs. H<sub>2</sub>O<sub>2</sub>.